arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

CorMedix Inc.

CRMD
$5.22 ▼ -0.43 (-7.61%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
72 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
94
Health
Excellent
Bullish
auto_awesome

Analytical Summary

CorMedix Inc. shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $409.5M
Dividend Yield —
Revenue Growth 156.5% ↘
Op. Margin 42.1% ↘
ROIC 6.2% ↘
FCF / Share $1.09 ↗
Trailing P/E 15.8x
Price / Book 0.9x
FCF Yield 20.9%
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

72-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$101.93M
↑ +156.5% —
Net Income Profit after all expenses
$25.99M
↑ +31.1% —
Operating Margin Operating profit as % of sales
42.1%
↓ -15.7% 97th
FCF / Share Free cash flow per share
$1.09
↑ +108.5% —
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
98
Returns
96
Financial Health
100
Cash Quality ↑
68

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 20 years · 72 quarters